Madrigal制药 MDGL 深 沪
等待开盘 07-29 09:30:00 美东时间
294.16
-4.240
-1.42%
华盛通- 最 高305.59
- 今 开299.57
- 成交量 29.25万股
- 最 低 293.85
- 昨 收 298.40
- 总市值 65.31亿
- 52周最高 377.46
- 市盈率 静 --
- 换手率 1.32%
- 52周最低 200.63
- 委 比 56.20%
- 总股本 2220.33万
- 历史最高 415.80
- 量 比 0.79
- 振 幅 3.93%
- 历史最低 5.25
- 每 手 1
- 风险率 41.62%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025
Madrigal Pharmaceuticals will release its Q2 2025 financial results on August 5, 2025, followed by a live webcast at 8 a.m. EDT to discuss the results. Madrigal, focused on MASH treatments, markets Rezdiffra, the first FDA-approved therapy for MASH with moderate to advanced fibrosis. An ongoing Phase 3 trial evaluates Rezdiffra for compensated MASH cirrhosis. Visit their website for more details.
07-25 12:00
Madrigal Pharmaceuticals Secures $500M Credit Facility
Madrigal Pharmaceuticals ( ($MDGL) ) just unveiled an update. On July 17, 2025,...
07-22 20:59
Madrigal Pharmaceuticals Announces It Has Entered Into A $500M Senior Secured Credit Facility With Funds Managed By Blue Owl Capital
Proceeds to primarily support MASH pipeline expansion and to refinance existing senior credit facility$350 million initial term loan funded at close and up to an additional $150 million available through 2027Agreement
07-22 20:02
Madrigal Pharmaceuticals Secures $500 Million in Senior Secured Credit from Blue Owl Managed Funds to Further Extend Leadership Position in MASH
Madrigal Pharmaceuticals entered a $500 million senior secured credit facility with Blue Owl Capital to support its MASH pipeline expansion and refinance existing debt. The financing includes a $350 million initial term loan, a $150 million delayed draw term loan through 2027, and an option for up to $250 million in additional facilities. This non-dilutive funding will help Madrigal advance its leadership in MASH therapies and strategic growth.
07-22 12:00
Madrigal gains after Rezdiffra patent win
Madrigal Pharmaceuticals (NASDAQ:MDGL) traded higher in the premarket on Wednesday after the company announced a patent win related to its lead asset, Rezdiffra, approved by the FDA in 2024 for a live...
07-16 20:54
Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra™ (Resmetirom)
Madrigal Pharmaceuticals获得专利，Rezdiffra FDA批准用于治疗非肝硬化NASH，专利保护至2044年9月，将列入FDA橙皮书。该专利涵盖药物的商业体重阈值剂量方案，符合FDA标签说明。公司CEO表示这是Rezdiffra长期战略的重要里程碑，将推动MASH治疗创新。
07-16 12:00
Madrigal, Viking among notable gainers after Altimmune’s MASH setback
Madrigal Pharmaceuticals (NASDAQ:MDGL) and Viking Therapeutics (NASDAQ:VKTX) were among notable gainers on Thursday as Altimmune (NASDAQ:ALT) boosted its rivals after posting a mixed outcome from a mi...
06-27 03:42
European Advisory Panel Backs Conditional Approval For Madrigal's Fatty Liver Disease Drug
Rezdiffra wins CHMP backing for conditional EU approval in MASH with fibrosis; decision from European Commission expected in August.
06-21 02:56
5 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. ...
06-21 01:35
Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis
The European Medicines Agency's CHMP has recommended approval of resmetirom (Rezdiffra) for treating noncirrhotic MASH with moderate to advanced fibrosis in Europe. The decision is expected by August 2025, making resmetirom the first MASH treatment in the EU if approved. The recommendation is based on positive results from the pivotal Phase 3 MAESTRO-NASH trial, which showed fibrosis improvement and MASH resolution. The U.S. FDA approved Rezdiffr...
06-20 10:30
